Back to Report Store Home

Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • Published: Oct-2016
  • Report Code: GBIHC422MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 11

2.1 Therapy Area Introduction 11

2.2 Symptoms 11

2.3 Etiology, Pathophysiology, Comorbidities and Complications 11

2.3.1 Hypertension 12

2.3.2 Dyslipidemia 14

2.3.3 Thrombotic events 15

2.4 Diagnosis 17

2.4.1 Hypertension 17

2.4.2 Dyslipidemia 17

2.4.3 Thrombotic events 18

2.5 Prognosis 18

2.6 Epidemiology Patterns and Forecasts – Prevalence and Patient Segmentation 19

2.6.1 Hypertension 20

2.6.2 Dyslipidemia 21

2.6.3 Thrombotic events 21

2.7 Treatment 22

2.7.1 Thiazide Diuretics 23

2.7.2 Angiotensin Converting Enzyme Inhibitors 24

2.7.3 Angiotensin Receptor Blockers 25

2.7.4 Calcium Channel Blockers 25

2.7.5 Statins 25

2.7.6 Anticoagulants 26

2.7.7 Antiplatelet Drugs 27

2.7.8 Beta-adrenoceptor antagonists (Beta blockers) 27

2.7.9 Other Drugs 28

3 Key Marketed Products 29

3.1 Overview 29

3.2 Crestor (rosuvastatin) – AstraZeneca 29

3.3 Zetia (ezetimibe) – Merck & Co 31

3.4 Lipitor (atorvastatin) – Pfizer 32

3.5 Praluent (alirocumab) – Sanofi 34

3.6 Xarelto (rivaroxaban) – Bayer 35

3.7 Eliquis (apixaban) – Bristol-Myers Squibb and Pfizer 37

3.8 Plavix (clopidogrel) – Sanofi 38

3.9 Brilinta (ticagrelor) – AstraZeneca 40

3.10 Entresto (valsartan plus sacubitril) – Novartis 41

3.11 Benicar (olmesartan medoxomil) – Daiichi Sankyo 42

3.12 Conclusion 44

4 Pipeline Landscape Assessment 45

4.1 Overview 45

4.2 Pipeline Development Landscape 45

4.3 Molecular Targets in the Pipeline 48

4.4 Clinical Trials 52

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 52

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 56

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 59

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 62

4.5 Conclusion 65

5 Multi-Scenario Market Forecast to 2022 66

5.1 Overall Market Size 66

5.2 Generic Penetration 67

5.3 Revenue Forecast by Molecular Target 69

5.3.1 Coagulation Cascade 70

5.3.2 P2Y12 Receptors 70

5.3.3 Beta 1 Adrenergic Receptors 71

5.3.4 PCSK9 Inhibitors 72

5.3.5 HMG-CoA Reductase Inhibitors (statins) 73

5.3.6 Renin angiotensin system (RAS) 74

5.3.7 Revenue and Market Share Analysis by Company 74

5.3.8 Assessment of Key Pipeline Products 85

6 Company Analysis and Positioning 92

6.1 Company Landscape 93

6.2 Marketed and Pipeline Portfolio Analysis 94

7 Strategic Consolidations 98

7.1 Licensing Deals 98

7.1.1 Deals by Region, Year and Value 98

7.1.2 Deals by Stage of Development and Value 100

7.1.3 Deals by Molecule Type, Mechanism of Action and Value 101

7.1.4 Licensing Deals Valued Above $200m 103

7.2 Co-development Deals 105

7.2.1 Deals by Region, Year and Value 105

7.2.2 Deals by Stage of Development and Value 106

7.2.3 Deals by Molecule Type, Mechanism of Action and Value 106

7.2.4 Co-development Deals Valued Above $100m 108

8 Appendix 110

8.1 References 110

8.2 Tables of All Pipeline Products 115

8.3 Table of Epidemiology Forecast 188

8.4 Abbreviations 190

8.5 Methodology 191

8.5.1 Coverage 191

8.5.2 Secondary Research 192

8.5.3 Market Size and Revenue Forecasts 192

8.5.4 Pipeline Analysis 192

8.5.5 Competitive Landscape 193

8.6 Contact Us 193

8.7 Disclaimer 193

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards